PubMed Health⌕ Search

Biomedical subjects

V Albarello

Publications and source records attributed to V Albarello.

4 recordsLinked to original sources

Estimated cerebral respiratory quotient and arteriovenous differences of CO2 in the ultra early detection of global ischemia in severe head injury.

The specificity of jugular bulb saturation (SjO2) and arteriovenous oxygen difference (AVDO2) to detect global cerebral ischemia remains controversial. An absolute increase in the arteriovenous difference of carbon dioxide tension (AVDpCO2) and, more specifically, the estimated respiratory quotient (eRQ = AVDpCO2/AVDO2) may indicate anaerobic CO2 production. We compared these variables with SjO2 to predict global cerebral ischemia. We selected 36 patients from a cohort of 69 consecutive patients suffering from severe traumatic brain injury. All patients had jugular bulb sampling within 6 hours after injury. Brain death at 48 hours was used as a surrogate index of irreversible ischemia to build a receiver operating characteristics (ROC) curve analysis. The mean (+/- standard deviation) eRQ in the 13 patients who died early (3.7 +/- 3.2 mmHg/ml/dl) was higher than the survivors (1.78 +/- 0.45 mmHg/ml/dl, P = 0.03). There was no differences in SjO2 between groups. The area under the ROC curves for eRQ, but not that of AVDpCO2, was greater (P = 0.04) than that of SjO2. The eRQ, more than AVDpCO2, appears to be a potentially more informative index of global cerebral ischemia than SjO2.

Adult↗

Transitory expansion of a CD3+TcR gamma/delta+CD16+ lymphocytic population in two patients with advanced human immunodeficiency virus infection and high levels of natural killer activity.

In the present study, we describe an expansion of CD16+ cells with a CD3+ TcR gamma/delta+ phenotype, in the presence of normal numbers of "classic" CD3-CD16+ natural killer (NK) cells, in two patients with human immunodeficiency virus (HIV) infection in late stage. The NK activity of the two subjects was substantially higher then that of HIV+ subjects in the same stage of infection. A second evaluation of one of the patients showed levels of NK activity consistent with the clinical stage of HIV infection, concomitant with a remarkable reduction in the percentage of double-positive CD3/TcR gamma/delta cells. The number of CD16+ cells also reached values comparable to those of the control group. In conclusion, we have identified a population of CD3+TcR gamma/delta+CD16+ cells that have the capability to lyse an NK-sensitive target in two patients with unusually high levels of NK activity.

Acquired Immunodeficiency Syndrome↗

Soluble interleukin-2 receptor decrease in the sera of HIV-infected patients treated with zidovudine.

Laboratory parameters which are modified following administration of zidovudine are becoming increasingly useful in monitoring the efficacy of treatment of early stages of HIV-1 infection. The serum levels of soluble interleukin (sILR)-2 receptor, which have been reported to increase early in HIV-1 infection, were found to be significantly lower in 24 patients being treated with zidovudine than in 69 patients who were not treated, 28 of whom had CD4+ counts greater than 400 x 10(6)/l, and 41 less than 400 x 10(6)/l, respectively (P less than 0.0001). A prospective study group of 33 subjects treated with zidovudine demonstrated a decrease in sIL-2R during therapy (base values 2113 +/- 1131 versus 1444 +/- 728 after 90 days of therapy; P less than 0.0007). The reduction of sIL-2R was greater in those subjects were p24 antigen became negative during treatment. sIL-2R therefore seems to be a useful tool in the monitoring of therapy with zidovudine.

CD4-Positive T-Lymphocytes↗